General Information of Drug (ID: DMW5V4U)

Drug Name
Enfortumab vedotin
Synonyms Padcev
Indication
Disease Entry ICD 11 Status REF
Urothelial carcinoma 2C92.0 Approved [1]
Bladder cancer 2C94 Phase 3 [2]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
DAG87H
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nectin cell adhesion molecule 4 (NECTIN4) TTPO9EG NECT4_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website.
2 ClinicalTrials.gov (NCT03474107) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). U.S.National Institutes of Health.
3 Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 Mar;72(2):165-182.